Mingrong Xia, Chenhao Gao, Junkui Shang, Dan Li, Ali Yang, Weizhou Zang, Jiewen Zhang
{"title":"1468年的一部小说一个中国汉族家庭的GRN突变导致额颞叶痴呆。","authors":"Mingrong Xia, Chenhao Gao, Junkui Shang, Dan Li, Ali Yang, Weizhou Zang, Jiewen Zhang","doi":"10.1186/s40001-025-02418-5","DOIUrl":null,"url":null,"abstract":"<p><strong>Background/purpose: </strong>GRN mutations act as causative factors in patients with FTD clinical phenotype or FTD pathology and exhibit high clinical heterogeneity. The discovery of these mutations and the analysis of their associations with resembling Alzheimer's disease should be critical to understand the pathogenesis of FTD.</p><p><strong>Methods: </strong>Clinical analysis, neuroimaging, target region capture and high-throughput sequencing were performed in a family of 3 generations. The underlying Alzheimer's pathology was evaluated by using biomarker evidence obtained from cerebrospinal fluid (CSF) amyloid testing, 18F-florbetapir (AV-45) PET imaging and FDG18-positron emission tomography imaging.</p><p><strong>Results: </strong>Through target region capture and high-throughput sequencing, a three-generation family was able to identify a heterozygous G to A point mutation at position 490 (c.1468)G > A, which led to a valine to methionine substitution (V490M) at exon 12. This unique missense mutation was found at codon 1468. Eight members of the proband's family-two sisters and the proband himself-had the mutation found by Sanger sequencing. Interestingly, biomarker tests for amyloid in the proband's cerebrospinal fluid (CSF) indicated pathology consistent with Alzheimer's disease (AD). The mutation was expected to have a high likelihood of being pathogenic.</p><p><strong>Conclusions: </strong>We firstly reported a novel mutation in the GRN gene at codon 490 (V490M) in exon 12 in a China FTD family. The CSF biomarker alterations of the proband revealed a reduction in Aβ42 and the Aβ42/Aβ40 ratio. The analysis of mutation might support the role of GRN in patients with FTD and contribute to the discovery of a new pathological mechanism underlying the disease.</p>","PeriodicalId":11949,"journal":{"name":"European Journal of Medical Research","volume":"30 1","pages":"157"},"PeriodicalIF":2.8000,"publicationDate":"2025-03-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11889931/pdf/","citationCount":"0","resultStr":"{\"title\":\"A novel c.1468 G > A GRN mutation causes frontotemporal dementia in a Chinese Han family.\",\"authors\":\"Mingrong Xia, Chenhao Gao, Junkui Shang, Dan Li, Ali Yang, Weizhou Zang, Jiewen Zhang\",\"doi\":\"10.1186/s40001-025-02418-5\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><strong>Background/purpose: </strong>GRN mutations act as causative factors in patients with FTD clinical phenotype or FTD pathology and exhibit high clinical heterogeneity. The discovery of these mutations and the analysis of their associations with resembling Alzheimer's disease should be critical to understand the pathogenesis of FTD.</p><p><strong>Methods: </strong>Clinical analysis, neuroimaging, target region capture and high-throughput sequencing were performed in a family of 3 generations. The underlying Alzheimer's pathology was evaluated by using biomarker evidence obtained from cerebrospinal fluid (CSF) amyloid testing, 18F-florbetapir (AV-45) PET imaging and FDG18-positron emission tomography imaging.</p><p><strong>Results: </strong>Through target region capture and high-throughput sequencing, a three-generation family was able to identify a heterozygous G to A point mutation at position 490 (c.1468)G > A, which led to a valine to methionine substitution (V490M) at exon 12. This unique missense mutation was found at codon 1468. Eight members of the proband's family-two sisters and the proband himself-had the mutation found by Sanger sequencing. Interestingly, biomarker tests for amyloid in the proband's cerebrospinal fluid (CSF) indicated pathology consistent with Alzheimer's disease (AD). The mutation was expected to have a high likelihood of being pathogenic.</p><p><strong>Conclusions: </strong>We firstly reported a novel mutation in the GRN gene at codon 490 (V490M) in exon 12 in a China FTD family. The CSF biomarker alterations of the proband revealed a reduction in Aβ42 and the Aβ42/Aβ40 ratio. The analysis of mutation might support the role of GRN in patients with FTD and contribute to the discovery of a new pathological mechanism underlying the disease.</p>\",\"PeriodicalId\":11949,\"journal\":{\"name\":\"European Journal of Medical Research\",\"volume\":\"30 1\",\"pages\":\"157\"},\"PeriodicalIF\":2.8000,\"publicationDate\":\"2025-03-08\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11889931/pdf/\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"European Journal of Medical Research\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.1186/s40001-025-02418-5\",\"RegionNum\":3,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q2\",\"JCRName\":\"MEDICINE, RESEARCH & EXPERIMENTAL\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"European Journal of Medical Research","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1186/s40001-025-02418-5","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"MEDICINE, RESEARCH & EXPERIMENTAL","Score":null,"Total":0}
引用次数: 0
摘要
背景/目的:GRN突变是FTD患者临床表型或病理的致病因素,且具有较高的临床异质性。发现这些突变并分析它们与类似阿尔茨海默病的关联对于了解FTD的发病机制至关重要。方法:对一个家族3代进行临床分析、神经影像学、靶区捕获和高通量测序。通过脑脊液(CSF)淀粉样蛋白检测、18F-florbetapir (af -45) PET成像和fdg18正电子发射断层扫描成像获得的生物标志物证据来评估潜在的阿尔茨海默病病理。结果:通过靶区捕获和高通量测序,一个三代家族能够在490 (c.1468)G > a位置发现一个杂合G to a点突变,该突变导致第12外显子的缬氨酸到蛋氨酸替换(V490M)。这个独特的错义突变是在密码子1468上发现的。先证者家族的八名成员——两个姐妹和先证者本人——都有桑格测序发现的突变。有趣的是,先证者脑脊液(CSF)中淀粉样蛋白的生物标志物测试表明病理与阿尔茨海默病(AD)一致。该突变被认为极有可能具有致病性。结论:我们首次报道了中国FTD家族12外显子密码子490 (V490M)的GRN基因突变。先证者的脑脊液生物标志物改变显示a - β42和a - β42/ a - β40比值降低。突变分析可能支持GRN在FTD患者中的作用,并有助于发现该疾病的新病理机制。
A novel c.1468 G > A GRN mutation causes frontotemporal dementia in a Chinese Han family.
Background/purpose: GRN mutations act as causative factors in patients with FTD clinical phenotype or FTD pathology and exhibit high clinical heterogeneity. The discovery of these mutations and the analysis of their associations with resembling Alzheimer's disease should be critical to understand the pathogenesis of FTD.
Methods: Clinical analysis, neuroimaging, target region capture and high-throughput sequencing were performed in a family of 3 generations. The underlying Alzheimer's pathology was evaluated by using biomarker evidence obtained from cerebrospinal fluid (CSF) amyloid testing, 18F-florbetapir (AV-45) PET imaging and FDG18-positron emission tomography imaging.
Results: Through target region capture and high-throughput sequencing, a three-generation family was able to identify a heterozygous G to A point mutation at position 490 (c.1468)G > A, which led to a valine to methionine substitution (V490M) at exon 12. This unique missense mutation was found at codon 1468. Eight members of the proband's family-two sisters and the proband himself-had the mutation found by Sanger sequencing. Interestingly, biomarker tests for amyloid in the proband's cerebrospinal fluid (CSF) indicated pathology consistent with Alzheimer's disease (AD). The mutation was expected to have a high likelihood of being pathogenic.
Conclusions: We firstly reported a novel mutation in the GRN gene at codon 490 (V490M) in exon 12 in a China FTD family. The CSF biomarker alterations of the proband revealed a reduction in Aβ42 and the Aβ42/Aβ40 ratio. The analysis of mutation might support the role of GRN in patients with FTD and contribute to the discovery of a new pathological mechanism underlying the disease.
期刊介绍:
European Journal of Medical Research publishes translational and clinical research of international interest across all medical disciplines, enabling clinicians and other researchers to learn about developments and innovations within these disciplines and across the boundaries between disciplines. The journal publishes high quality research and reviews and aims to ensure that the results of all well-conducted research are published, regardless of their outcome.